MCU - I realize its cheap, but MCU does not have to charge alot due to the market size. Seems like the price would be an incentive to add it to the protocol for any patient undergoing a cardiac procedure. Risk vs benefits would heavily weigh in favor of MC-1.
The Phase II trial FAILED. The Phase II trial showed no change in MORTALITY. The current trial will likely also show no benefit in MORTALITY. The subset in which they claimed statistical significance from my guess is likely n<50 from 900 patients.
Market Data 
Markets 
AI
